8-K ·Filed Jul 22, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001664710-26-000038
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine CFO departure with an internal interim replacement and no severance cost — limited near-term stock impact. Monitor the search for a permanent CFO and any subsequent 10-Q filing for financial statement continuity.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
KROS ▲ +7.99% at T+20d
NEUTRAL call ✓ call won +7.99% · α vs SPY +4.68% · entry $10.14 → $10.95
Next anchor: T+60d in 13d
Latest observation: T+49 +31.50% FF3 residual α
Entry anchored
Jul 22, 03:59 PM ET
via exchange tick
T+1d
-0.79%
call -0.79% · α -0.89%
$10.06
settled 2mo ago
T+5d
+0.79%
call +0.79% · α +0.31%
$10.22
settled 2mo ago
T+20d
+7.99%
call +7.99% · α +4.68%
$10.95
settled 6w ago
T+60d
—
call — · α —
—
in 13d

Price Chart

Loading chart...

Executive Summary

CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities. Corporate Controller Annita Tanini was appointed interim principal financial and accounting officer effective August 4, 2026, with a base salary of $302,300. The company has commenced a search for a permanent CFO. The departure is stated as voluntary with no disagreement over accounting or operations, and Regnante receives no severance beyond accrued pay and COBRA eligibility.

Key Facts

  • CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities.
  • Annita Tanini, Corporate Controller and VP of Finance, appointed interim principal financial and accounting officer effective August 4, 2026.
  • Regnante's resignation is voluntary with no disagreement over accounting, financials, or internal controls.
  • Regnante receives no severance — only accrued base salary, expense reimbursement, and COBRA continuation at his own expense.
  • Tanini's compensation: $302,300 base salary, 30% target bonus, and six months severance on qualifying termination.
  • Company has commenced a search for a permanent CFO.

Financial Impact

No material financial impact disclosed. CFO transition with interim appointment and no severance payout.

Risk Factors

  • Extended CFO vacancy could delay financial reporting or strategic decisions.
  • Interim CFO may lack public company CFO experience, increasing execution risk during the search period.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000038
Document: 0001664710-26-000038-index-headers.html0001664710-26-000038
Document: 0001664710-26-000038-index.html0001664710-26-000038
Document: 0001664710-26-000038.txt0001664710-26-000038
17 reports for KROS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+5▲ +10.72%Jul 30, 2026
Filters
Rows
Reports for KROS — sortable, filterable
TypeNow
Sep 8, 2026
23d ago
8-K
NEUTRAL ★ 4/10
$11.31 $11.04▼ −2.39%▼ −2.05%$11.33 (+0.18%)
Aug 20, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$10.95 $11.23▲ +2.56%▲ +1.44%$11.33 (+3.47%)
Aug 3, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$10.25 $10.64▲ +3.80%▲ +3.90%$11.33 (+10.54%)
Aug 3, 2026
8w ago
Press Release
NEUTRAL ★ 3/10
$10.25 $10.64▲ +3.80%▲ +3.90%$11.33 (+10.54%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 6/10
$10.07 $11.15▲ +10.72%▲ +7.21%$11.33 (+12.51%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$10.14 $10.22▲ +0.79%▲ +0.31%$11.33 (+11.74%)
Jun 17, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$10.65 $10.41▼ −2.25%▼ −0.59%$11.33 (+6.38%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$10.07 $10.24▲ +1.69%▼ −0.72%$11.33 (+12.51%)
May 14, 2026
20w ago
8-K
BEARISH ★ 5/10
$10.99 $11.22▼ −2.09%▼ −2.81%$11.33 (−3.09%)
May 14, 2026
20w ago
Press Release
BEARISH ★ 6/10
$10.99 $11.22▼ −2.09%▼ −2.81%$11.33 (−3.09%)
Showing 10 of 17

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access